

Online Table: Demographic and clinical characteristics

	HC (n = 19)	Total MS (n = 30)	RRMS (n = 23)	PMS (n = 7)	MS vs HC ^a (P Value)	RRMS vs PMS (P Value)
Age (mean) (range) (yr) ¹⁵	39.9 ± 11.4 (23–61)	43.9 ± 11.2 (23–60)	42.6 ± 10.6 (23–58)	48.1 ± 12.8 (26–60)	.81 ^b	.32 ^b
Female (No.) (%)	10 (53%)	24 (80%)	19 (83%)	5 (71%)	.04 ^c	.52 ^c
Disease duration (mean) (range) (yr) ¹⁵	NA	10.8 ± 6.7 (1–23)	10.3 ± 6.7 (1–23)	12.3 ± 6.9 (4–23)	NA	.52 ^b
Disease-modifying therapy (No.) (%)	NA	26 (87%)	21 (91%)	5 (71%)	NA	.27 ^c
Dimethyl fumarate		8	8	0		
Glatiramer acetate		6	6	0		
β-interferons		4	3	2		
Fingolimod		3	2	1		
Natalizumab		2	2	0		
Rituximab		2	0	2		
Ocrelizumab		1	1	0		
None		4	2	2		
EDSS score (mean) (range) ⁴¹	NA	3.0 ± 1.9 (1–7.5)	2.1 ± 0.8 (1–3.5)	5.8 ± 1.6 (3–7.5)	NA	<.001 ^d
MSFC-3 (mean) (range) ⁴¹	NA	−0.54 ± 2.06 (−6.21–1.08)	0.30 ± 0.52 (−0.80–1.08)	−3.29 ± 2.82 (−6.21 to −0.05)	NA	.002 ^d

Note:—NA indicates not applicable.

^a Entire MS sample.

^b Student *t* test.

^c χ^2 test.

^d Wilcoxon rank sum test.